Blocking Ephrin-B2 reverses VEGFR2 signaling and is considered an attractive alternative or combinatorial antiangiogenic therapy strategy for disrupting VEGFR2 function in tumor angiogenesis [18]. This evidence concerns the gene EFNB2 and neoplasm.